Fig. 1From: Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritisTime course of disease activity scores over 24 weeks of tofacitinib and baricitinib treatments. Points and bars represent means and standard deviations, respectively. *,†P < 0.0001 vs baseline by the Wilcoxon signed rank test. ESR erythrocyte sedimentation rate, DAS disease activity scoreBack to article page